Abstract
In the last decade, nicotinic acetylcholine receptors (nAChRs) have emerged as important targets for drug discovery. The therapeutic potential of nicotinic agonists depends substantially on the ability to selectively activate certain receptor subtypes that mediate beneficial effects. The design of such compounds has proceeded in spite of a general shortage of data pertaining to subtype selectivity. Medicinal chemistry efforts have been guided principally by binding affinities to the α4β2 and/or α7 subtypes, even though these are not predictive of agonist activity at either subtype. Nevertheless, a diverse family of nAChR ligands has been developed, and several analogs with promising therapeutic potential have now advanced to human clinical trials. This paper provides an overview of the structure-affinity relationships that continue to drive development of new nAChR ligands.
Keywords: Nicotine, epibatidine, acetylcholine, quinuclidine, nAChR, α4β2, α7, SAR
Related Journals
Current Chinese Science
Anti-Cancer Agents in Medicinal Chemistry
Current Computer-Aided Drug Design
Current Bioactive Compounds
Current Medicinal Chemistry
Current Topics in Chemistry
The Natural Products Journal
Current Catalysis
Current Chinese Chemistry
Combinatorial Chemistry & High Throughput Screening
Related Books
A Journey Through Water: A Scientific Exploration of The Most Anomalous Liquid on Earth
Advances in Mathematical Chemistry and Applications
Advances in Mathematical Chemistry and Applications
Advances in Mathematical Chemistry and Applications Volume 1 (Revised Edition)
Advances in Organic Synthesis
Advances in Organic Synthesis
Advances in Organic Synthesis
Advances in Organic Synthesis
Advances in Organic Synthesis
Advances in Organic Synthesis